NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Compass Therapeutics, Inc. (CMPX) Stock Analysis

Compass Therapeutics, Inc. (CMPX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CMPX

$0.81

−$0.02 (−2.26%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CMPX with… →

CMPX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.82
Previous Close
$0.83
Day's Range
0.81–0.84
52-Week Range
0.82–6.88
Volume
1.54M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.91
Valuation
Market Cap
$158.30M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.39
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$66.49M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
180.09M
1-Year Return
−80.13%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.22M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CMPX closed at $0.81, −80.13% over 1 year.

Compass Therapeutics, Inc. (CMPX) has a market capitalization of $158.30M.

In fiscal 2025, CMPX reported revenue of $0.00.

CMPX Stock Return by Calendar Year

Compass Therapeutics, Inc. (CMPX) return since Apr 2021: what $10,000 became

1 year
$10,000 $1,987
−80.13%
5 years
$10,000 $2,506
−74.94%
Since Apr 2021
$10,000 $958
−90.42%

If you had invested $10,000 in Compass Therapeutics, Inc. (CMPX) at the close on April 5, 2021, the earliest close on record here, it would have been worth $958 at the close on October 21, 2026: −90.42% in total, −34.49% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−84.83%
2025+270.34%
2024−7.05%
2023−68.99%
2022+58.68%
2021 (partial year)−62.71%

As of October 21, 2026.

CMPX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$66.49M—
2024$850.00K−$49.38M−5,808.8%
2023$0.00−$42.49M—
2022$0.00−$39.23M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$72.84M−$66.49M—
2024$850.00K—−$56.63M−$49.38M−5,808.8%
2023$0.00—−$50.36M−$42.49M—
2022$0.00—−$41.66M−$39.23M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Compass Therapeutics, Inc. (CMPX) is capitalised at $158.30M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 39.

The 52-week range on file runs from $0.82 to $6.88. The most recent close on file for CMPX is $0.81, dated October 21, 2026. That is −$0.02 (−2.26%) against the previous close.

Financial Health

In fiscal 2025, Compass Therapeutics, Inc. reported revenue of $0.00. Against the prior fiscal year total of $850.00K, that is a change of −100.00%. The same year closed with a net loss of $66.49M. Earnings per share on a trailing basis come to −0.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −80.13%. Measured over 5 years, that is −24.18% a year compounded. Beta against the wider market is reported at 0.91. Annualized volatility over the trailing 5 years is 88.06%.

Growth & Income

No dividend is on file for CMPX.

The strongest complete calendar year on file is 2025 at +270.34%; the weakest is 2023 at −68.99%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −84.83%.

Peer Comparison

Compass Therapeutics, Inc. (CMPX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Compass Therapeutics, Inc. CMPX $158.30M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Compass Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Visit website →